2026-07-22T20:10:42Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/252662025-03-20T10:55:02Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16958
Repisalud
author
Salguero-Aranda, Carmen
author
Amaral, Ana Teresa
author
Olmedo-Pelayo, Joaquín
author
Diaz-Martin, Juan
author
Álava, Enrique De
2024-10-23T13:07:20Z
2024-10-23T13:07:20Z
2020-03-26
10.3390/cells9040804
2073-4409
Cells
http://hdl.handle.net/10668/15303
32225029
https://hdl.handle.net/20.500.12105/25266
Ewing sarcoma is a highly aggressive round cell mesenchymal neoplasm, most often occurring in children and young adults. At the molecular level, it is characterized by the presence of recurrent chromosomal translocations. In the last years, next-generation technologies have contributed to a more accurate diagnosis and a refined classification. Moreover, the application of these novel technologies has highlighted the relevance of intertumoral and intratumoral molecular heterogeneity and secondary genetic alterations. Furthermore, they have shown evidence that genomic features can change as the tumor disseminates and are influenced by treatment as well. Similarly, next-generation technologies applied to liquid biopsies will significantly impact patient management by allowing the early detection of relapse and monitoring response to treatment. Finally, the use of these novel technologies has provided data of great value in order to discover new druggable pathways. Thus, this review provides concise updates on the latest progress of these breakthrough technologies, underscoring their importance in the generation of key knowledge, prognosis, and potential treatment of Ewing Sarcoma.
eng
DNA repair
Ewing sarcoma
GF
Breakthrough technologies
Circulating tumor DNA/RNA
Extracellular vesicles
Mutations
Sarcoma
Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape.
research article